Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.48 |
| ▸ | BRAF | P15056 | 8/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | KIF5B | P33176 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15065804 | 0.85 | RAF1 (0.46) | RAF1BRAFBRD4DRD2DRD4 | |
| SCHEMBL30078033 | 0.85 | RAF1 (0.46) | RAF1BRAFBRD4DRD2DRD4 | |
| SCHEMBL15068428 | 0.83 | KDM4E (0.43) | RAF1BRAFKDM4ERAB9ATUBB1 | |
| SCHEMBL29477090 | 0.79 | ERN1 (0.48) | KDM4ERAB9ATUBB1ALDH1A1 | |
| SCHEMBL15065581 | 0.79 | ERN1 (0.48) | KDM4ERAB9ATUBB1ALDH1A1 | |
| SCHEMBL29477098 | 0.77 | RAB9A (0.40) | RAF1BRAFKDM4ERAB9ATUBB1 | |
| SCHEMBL15065281 | 0.77 | RAB9A (0.40) | RAF1BRAFKDM4ERAB9ATUBB1 | |
| SCHEMBL30077992 | 0.76 | DRD2 (0.38) | RAF1BRAFBRD4DRD2DRD4 | |
| SCHEMBL15065952 | 0.76 | DRD2 (0.38) | RAF1BRAFBRD4DRD2DRD4 | |
| SCHEMBL23680091 | 0.76 | RAB9A (0.46) | KDM4ERAB9ATUBB1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255963-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | claimed |
| US-20220125786-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | claimed |
| US-20210290619-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-09-23 | — | — | US | claimed |
| US-20150344472-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-12-03 | — | — | US | claimed |
| EP-2797416-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | claimed |
| US-20130190315-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | claimed |
| WO-2013102142-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | claimed |
| EP-4289813-A2 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289813-A2 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-3738434-B1 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230255963-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-2797416-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20130190315-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190315-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013102142-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013102142-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | RAF1 3962/4885BRAF 3363/4885KDM4E 1701/4885 |
| US-20150344472-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | RAF1 4197/4885BRAF 2625/4885KDM4E 863/4885 |
| US-20230255963-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | RAF1 4197/4885BRAF 2625/4885KDM4E 863/4885 |
| US-20220125786-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | RAF1 4197/4885BRAF 2625/4885KDM4E 863/4885 |
| US-20130190315-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | RAF1 4197/4885BRAF 2625/4885KDM4E 863/4885 |
| US-20210290619-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | RAF1 4197/4885BRAF 2625/4885KDM4E 863/4885 |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | RAF1 3962/4885BRAF 3363/4885KDM4E 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.